表紙
市場調査レポート

未熟児網膜症 : パイプライン分析

Retinopathy Of Prematurity - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 255964
出版日 ページ情報 英文 53 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
未熟児網膜症 : パイプライン分析 Retinopathy Of Prematurity - Pipeline Review, H1 2016
出版日: 2016年03月31日 ページ情報: 英文 53 Pages
概要

未熟児網膜症(ROP)とは、未熟児の網膜脈管の発達を妨げる疾患です。通常は両眼のどちらにも現れ、幼児期の失明や長期的な視力低下の最も一般的な要因となっています。未熟児網膜症発症のリスク要因として、早産や超低出生体重、多胎出産などが挙げられます。

当レポートでは、世界各国での未熟児網膜症治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査して、その結果を概略以下の構成でお届けします。

目次

イントロダクション

  • 分析範囲

未熟児網膜症の概要

治療薬の開発

  • 未熟児網膜症向けパイプライン製品:概要
  • 未熟児網膜症向けパイプライン製品:比較分析

各企業で開発中の未熟児網膜症治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

未熟児網膜症治療薬:開発中の製品の一覧(企業別)

未熟児網膜症治療薬の開発に従事している企業

  • Acucela Inc.
  • Biomar Microbial Technologies
  • EyeGene, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gene Signal International SA
  • Insmed Incorporated

未熟児網膜症:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 機能メカニズム別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • aganirsen
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • EG-Mirotin
  • emixustat hydrochloride
  • IB-09A0133
  • mecasermin rinfabate (recombinant)
  • R-200
  • ranibizumab
  • 未熟児網膜症向け治療薬

未熟児網膜症治療薬:パイプライン製品の最新動向

未熟児網膜症関連の製品開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7776IDB

Summary

Global Markets Direct's, 'Retinopathy Of Prematurity - Pipeline Review, H1 2016', provides an overview of the Retinopathy Of Prematurity pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Retinopathy Of Prematurity, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Retinopathy Of Prematurity and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Retinopathy Of Prematurity
  • The report reviews pipeline therapeutics for Retinopathy Of Prematurity by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Retinopathy Of Prematurity therapeutics and enlists all their major and minor projects
  • The report assesses Retinopathy Of Prematurity therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Retinopathy Of Prematurity

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Retinopathy Of Prematurity
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Retinopathy Of Prematurity pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Retinopathy Of Prematurity Overview
  • Therapeutics Development
    • Pipeline Products for Retinopathy Of Prematurity - Overview
  • Retinopathy Of Prematurity - Therapeutics under Development by Companies
  • Retinopathy Of Prematurity - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Retinopathy Of Prematurity - Products under Development by Companies
  • Retinopathy Of Prematurity - Companies Involved in Therapeutics Development
    • Acucela Inc.
    • Biomar Microbial Technologies
    • F. Hoffmann-La Roche Ltd.
    • Gene Signal International SA
    • Insmed Incorporated
  • Retinopathy Of Prematurity - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • aganirsen - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AP-202 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • emixustat hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IB-09A0133 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • mecasermin rinfabate (recombinant) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • R-200 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ranibizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein for Cancer and Diabetic Retinopathy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Retinopathy of Prematurity - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Retinopathy Of Prematurity - Recent Pipeline Updates
  • Retinopathy Of Prematurity - Dormant Projects
  • Retinopathy Of Prematurity - Product Development Milestones
    • Featured News & Press Releases
      • Jan 21, 2009: Insmed And Premacure Announce European Orphan Designation For IPLEX In Retinopathy Of Prematurity In Infants
      • Apr 29, 2008: Acucela Presents Preclinical Data From Retinopathy Study Demonstrating Improvement In Retinal Abnormalities
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Retinopathy Of Prematurity, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Retinopathy Of Prematurity - Pipeline by Acucela Inc., H1 2016
  • Retinopathy Of Prematurity - Pipeline by Biomar Microbial Technologies, H1 2016
  • Retinopathy Of Prematurity - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Retinopathy Of Prematurity - Pipeline by Gene Signal International SA, H1 2016
  • Retinopathy Of Prematurity - Pipeline by Insmed Incorporated, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Retinopathy Of Prematurity Therapeutics - Recent Pipeline Updates, H1 2016
  • Retinopathy Of Prematurity - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Retinopathy Of Prematurity, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top